Skip Ribbon Commands
Skip to main content

Dr. Mutasem Taha


Shared Documents :All DocumentsUse SHIFT+ENTER to open the menu (new window).Open MenuOpen Menu

Share a document with the team by adding it to this document library.
Berberine potently inhibits protein tyrosine phosphatase 1B Invetigation by docking and experimental validation.pdf
2/5/2010 11:04 AMMutasem Taha
caryophyllene reduces endometriosis.pdf
3/15/2013 11:51 PMMutasem Taha
Combining docking, scoring and molecular field analyses to probe flu neuraminidase.pdf
1/9/2010 3:23 PMMutasem Taha
Combining Ligand-Based Pharmacophore Modeling, Quantitative Structure-Activity to discover new HSL inhibitors.pdf
1/9/2010 3:33 PMMutasem Taha
dbCICA as New 3D QSAR for validating docking and generating phamracophores.pdf
9/4/2011 6:00 PMMutasem Taha
dbCICA fo HSP90-journal of molecular modelling.pdf
6/20/2012 2:23 PMMutasem Taha
Design Synthesis and Biological Evaluation of NEW DPP4 inhibitors.pdf
12/22/2013 8:44 AMMutasem Taha
Design synthesis and evaluation of sulfonic acid ester and benzenesulfonamides as CETP inhibitors.pdf
10/8/2012 9:17 AMMutasem Taha
Development of predictive in silico model for cyclosporine- based Pgp inhibitors employing RSA.pdf
1/9/2010 3:30 PMMutasem Taha
Development of QSPR models for   microemulsions formulated using nonionic surfactants.pdf
1/15/2010 10:11 AMMutasem Taha
Discovery of New Antifungal Leads via Pharmacophor  and QSAR Analysis of NMT Inhibitors AND In Silico Screening.pdf
8/23/2011 12:06 AMMutasem Taha
Discovery of new CETP inhibitors via pharmacophore  and QSAR then synthetic exploration.pdf
3/4/2010 3:56 AMMutasem Taha
Discovery of New galactosidase Inhibitors via Pharmacophore Modeling and QSAR Analysis followed by In Silico Screening.pdf
1/16/2011 12:08 AMMutasem Taha
Discovery of new MurF inhibitors via pharmacophore modeling and QSAR.pdf
1/9/2010 3:18 PMMutasem Taha
Discovery of new nanomolar PPARgamma activators.pdf
4/25/2011 1:35 PMMutasem Taha
Discovery of new potent human protein tyrosine phosphatase  via pharmacophore and QSAR.pdf
1/9/2010 3:22 PMMutasem Taha
Discovery of new renin inhibitory leads via sequential pharmacophore modeling.pdf
4/6/2011 6:23 PMMutasem Taha
Discovery of novel CDK1 inhibitors by combining pharmacophore modeling and QSAR.pdf
8/11/2010 2:30 PMMutasem Taha
Discovery of novel urokinase plasminogen activator (uPA) inhibitors.pdf
12/15/2013 5:02 PMMutasem Taha
Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore  modelling.pdf
1/9/2010 3:20 PMMutasem Taha
Effects of Variable Docking Conditions and Scoring Functions on CoMFA.pdf
1/9/2010 3:16 PMMutasem Taha
Elaborate Ligand-Based Modeling Reveals New Nanomolar Heat Shock Protein 90alpha inhibitors.pdf
10/2/2010 1:56 PMMutasem Taha
Ethosuximide and Phenobarbital Promote Wound HEALING.pdf
11/10/2011 3:04 PMMutasem Taha
9/28/2010 10:23 AMMutasem Taha
Evaluation of naprroxen and cromolyn against cancer.pdf
10/6/2013 3:52 PMMutasem Taha
Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.pdf
5/22/2012 6:22 PMMutasem Taha
Formulation and Characterization of IPMWater Nonionic-Ionic Surfactant Microemulsions .PDF
3/14/2012 4:34 PMMutasem Taha
Homology modeling of MCH1 receptor and validation by docking-scoring and CoMFA.pdf
1/9/2010 3:35 PMMutasem Taha
in silico screening reveal new potent acetylcholinesterase INHIBITORS.pdf
12/15/2013 4:58 PMMutasem Taha
In vitro alpha amylase inhibitory effect of some clinically-used drugs.pdf
2/5/2010 11:06 AMMutasem Taha
3/14/2012 4:50 PMMutasem Taha
Ligand-based assessment of factor Xa binding site flexibility.pdf
1/9/2010 3:12 PMMutasem Taha
ligand-based modelling And synthesis unveil new CAMKII inhibitors.pdf
12/29/2011 8:46 PMMutasem Taha
Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.pdf
8/3/2011 4:57 PMMutasem Taha
Ligand-based modelling unveils new rho kinase inhibitors.pdf
12/16/2011 1:36 PMMutasem Taha
4/30/2012 4:47 PMMutasem Taha
Naproxen and Cromolyn New Glycogen Synthase inhibitors for obesity .pdf
10/6/2013 3:58 PMMutasem Taha
new glucosidase inhibitors via pharmacophormodeling and QSAR.pdf
7/3/2010 2:35 PMMutasem Taha
new leads for DPP inhibition.pdf
10/6/2013 3:49 PMMutasem Taha
1/9/2010 3:09 PMMutasem Taha
novel ionotropically crosslinked beads based on aliginate-terphthalate.pdf
12/15/2013 4:59 PMMutasem Taha
pharmacophore and QSAR guide synthesis of pyridinium based BACE inhibitorS.pdf
4/27/2010 9:51 AMMutasem Taha
Pharmacophore and QSAR Modeling of eNOS Inhibitors and Subsequent Validation and In Silico Search for New Hits.pdf
9/26/2012 2:29 PMMutasem Taha
Pharmacophore and QSAR modeling of estrogen receptor B ligands.pdf
1/9/2010 3:52 PMMutasem Taha
Pharmacophore Modeling Quantitative Structure–Activity Relationship Analysis for GSK inhibitors,.pdf
1/9/2010 3:14 PMMutasem Taha
Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, for the discovery of new Flu NA inhibitors.pdf
2/2/2010 3:23 AMMutasem Taha
pharmacophore modelling aand QSAR for new MIF inhibitors.pdf
4/18/2013 11:38 AMMutasem Taha
pharmacophore modelling and MLR-KNN-based QSAR for new mTOR inhibitors.pdf
10/6/2013 3:39 PMMutasem Taha
pharmacophore modelling and QSAR analysis discovery anti-mTOR activities for some common drugs.pdf
3/30/2013 3:05 PMMutasem Taha
pharmacophore modelling and QSAR analysis yield potent TSA beta secretase inihibitors .pdf
2/23/2013 2:54 PMMutasem Taha
Phenytoin enhances collagenization in excision wounds.pdf
2/1/2010 3:04 AMMutasem Taha
1/24/2011 11:58 AMMutasem Taha
Preparation and in vitro characterization of glibenclamide loaded alginate hexylamide beads.pdf
10/6/2013 3:41 PMMutasem Taha
Preparation of Silver- and Zinc-Doped Mullite-Based Ceramics of antibacterial properties .pdf
4/1/2011 3:25 PMMutasem Taha
published paper Famotidine inhibits glycogen synthase kinase.pdf
10/6/2013 4:05 PMMutasem Taha
QSPR modeling of pseudoternary microemulsions formulated using lecithin.pdf
1/9/2010 3:25 PMMutasem Taha
Rational exploration of new pyridinium-based HSP90a inhibitors Tailored to thiamin structure-Proofs .pdf
1/16/2011 9:06 AMMutasem Taha
Regression of endometrial implants treated with vitamin D3.pdf
10/6/2013 3:50 PMMutasem Taha
Release of ephedrine from mesoporous MCM-41 materials.pdf
12/16/2011 1:40 PMMutasem Taha
Sodium lauryl sulfate impedes drug release from zinc-crosslinked alginate beads.pdf
1/9/2010 3:29 PMMutasem Taha
Some Sulfonamide drugs inhibit ATPase activity of Hsp90.pdf
12/30/2010 7:03 AMMutasem Taha
Sunitinib as an anti-endometriotic agent.pdf
10/6/2013 4:01 PMMutasem Taha
Synthesis and biological activity assays of some new flavon amidrazones.pdf
7/30/2012 1:33 AMMutasem Taha
Synthesis of Chitosan Succinate and Chitosan Phthalate and their evaluation as colon-delivery matrices.pdf
3/12/2012 3:02 PMMutasem Taha
synthesis of ion-crosslinked hydroxamated alginic acid.pdf
10/20/2012 11:05 AMMutasem Taha
Synthesis of new derivatives of alginic acid and their iron crosslinked beads as controlled release matrices.pdf
10/6/2013 3:46 PMMutasem Taha
synthesis of novel chitosan-based polymers using Ugi reaction and use as drug delivery system.pdf
6/17/2013 8:47 AMMutasem Taha
Synthesis of zinc-crosslinked thiolated alginic acid beads.pdf
3/10/2010 5:41 AMMutasem Taha
Thujone corrects cholesterol and triglycerides in diabetic rate models.pdf
7/17/2011 6:04 PMMutasem Taha